Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Travere Therapeutics Inc (NQ: TVTX )

18.77 +0.07 (+0.37%)
Streaming Delayed Price Updated: 9:51 AM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
The company previously had an accelerated approval for its IgA nephropathy treatment. 
Via Investor's Business Daily
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
Posters to be presented highlight clinical study designs investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria 
From Travere Therapeutics, Inc.
Via GlobeNewswire
Expert Ratings For Travere Therapeutics
Via Benzinga
Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts
Via Benzinga
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Travere Therapeutics Reports Second Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
Via Benzinga
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
Via Benzinga
Travere Therapeutics to Report Second Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024
TVTX stock results show that Travere Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Travere Therapeutics Reports First Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report First Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Posters to be presented highlighting research investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria 
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease (RKD) 
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Submission is based on 2-year confirmatory results from the Phase 3 PROTECT Study in which FILSPARI demonstrated a significant reduction in proteinuria, preservation of kidney function and a generally... 
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.